image196
Thank you for visiting

Welcome to BiOTECHVORTEX™

The www.biotechvortex.com section of the site I started when I started seeing the connections, links, partnerships, new technologies and mergers that were taking place in the biotech sector. Thank you for visiting.  Vortexes are powerful and transformational centers of energy.

image197

BiotechVortex™

 

A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.


Biotech & Biotech Partnerships.


Biotech & Medtech Partnerships.


Biotech & Medtech & Medical 

Universities Partnerships.


Biotech & Health Systems Partnerships.

 

BiotechVortex™

Moderna (MRNA) & Harvard University

image198

 

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

September 26, 2019 at 8:00 AM EDTPDF Version

Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities  

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2019-- Moderna, Inc., (Nasdaq: MRNA)

 https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-mrna-immunotherapy-research-collaboration 


 September 26, 2019

Harvard University establishes mRNA immunotherapy research collaboration with Moderna

Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities

Cambridge, Mass. - September 26, 2019 Harvard University

 https://otd.harvard.edu/news/harvard-university-establishes-mrna-immunotherapy-research-collaboration-wi 


 

Moderna collaborates with Harvard University for immunology programs

Sep. 26, 2019 8:42 AM ET|About: Moderna, Inc. (MRNA)|By: , SA News Editor 

 https://seekingalpha.com/news/3502018-moderna-collaborates-harvard-university-immunology-programs 


 
https://www.modernatx.com/pipeline  


Dragonfly Therapeutics Announces Collaboration with AbbVie

image199

 

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Wed November 20, 2019 8:00 AM|PR Newswire|About: ABBV

Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology.  AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies.

WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly Therapeutics


 https://www.dragonflytx.com/ 


 https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology-300961954.html 


 https://www.dragonflytx.com/about-us 

image200

image201

image202

image203

BiotechVortex™

Bristol-Myers Squibb and Pfizer

image204

 

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals

Fri November 15, 2019 9:00 AM|Business Wire|About: PFE

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- The Bristol-Myers Squibb-Pfizer Alliance 


 https://www.businesswire.com/news/home/20191115005062/en/ 



 https://my.clevelandclinic.org/health/articles/13398-know-your-risk-factors-for-stroke 



Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4B

 

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

Mon August 26, 2019 6:30 AM|Business Wire|About: AMGN, BMY, CELG

Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger

Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) announced today that Celgene Corporation (CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash.


 https://www.businesswire.com/news/home/20190826005247/en/ 


 https://seekingalpha.com/news/3519945-ftc-board-bristol-myers-celgene-tie-otezla-sale 



image205

 

Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Mon November 18, 2019 6:00 AM|Business Wire|About: DRNA

– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates –

– Each Company to Retain Rights to Co-Develop and

Co-Commercialize Product Candidates –

– Dicerna to Receive Upfront Payment of USD 175 Million and

Equity Investment of USD 50 Million –

– Dicerna is Eligible to Receive an Additional USD 75 Million Over the First Three Years, Plus Up to USD 357.5 Million per Target in Potential Milestone Payments, and Royalties on Product Sales –

– Dicerna to Host Conference Call Today at 8:00 a.m. ET –

LEXINGTON, Mass., & BAGSVÆRD, Denmark--(BUSINESS WIRE)-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) and Novo Nordisk A/S 


 https://dicerna.com/ 


 https://www.businesswire.com/news/home/20191118005269/en/ 


  novonordisk.com 

Vertex and Molecular Templates Establish Collaboration

image206

 

Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

Mon November 18, 2019 7:00 AM|GlobeNewswire|About: MTEM 

 

-Molecular Templates (MTEM) to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-

BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.


 https://mtem.com/ 


 https://www.vrtx.com/ 


 https://mtem.com/etb-platform/pipeline/ 

ORION-10 Study of Inclisiran

image208

 

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Sat November 16, 2019 10:45 AM|Business Wire|About: MDCO

- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD)

- ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities

- Results presented today during late-breaking science session at American Heart Association annual meeting in Philadelphia

- The Medicines Company (MDCO) to host investor conference call and webcast on Monday, November 18, 12:00 pm EST

PHILADELPHIA--(BUSINESS WIRE)


 https://www.themedicinescompany.com/ 


 https://seekingalpha.com/news/3520048-medicines-company-2-percent-premarket-positive-inclisiran-data 



BiotechVortex™

Editas Medicine and Celgene Corporation

image209

 

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

Tue November 12, 2019 7:00 AM|GlobeNewswire|About: EDIT

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

Editas Medicine (EDIT) to receive a $70 million payment and may be eligible for future milestone and royalty payments

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced an amended collaboration with Celgene Corporation (Nasdaq: CELG) 



CABOMETYX® (cabozantinib)

image210

 

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

Tue November 12, 2019 8:02 AM|Business Wire|About: EXEL

– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (NASDAQ:EXEL)


 https://www.businesswire.com/news/home/20191112005303/en/ 


 https://ir.exelixis.com/news-releases/news-release-details/exelixis-partner-ipsen-announces-health-canadas-approval-0 



 https://www.ipsen.com/partnering/ 


 https://www.exelixis.com/ 



Celgene inks second collaboration deal with Skyhawk

image211

 

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Tue November 12, 2019 9:00 AM|PR Newswire|About: CELG

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets. 

Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and royalties.

WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (CELG)


 https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-a-second-multi-target-collaboration-agreement-with-celgene-to-discover-and-develop-novel-small-molecules-that-modulate-rna-splicing-300956283.html 

Exicure (NASDAQ:XCUR) will collaborate with Allergan (NYSE:AGN)

image212

 

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Thu November 14, 2019 7:00 AM|Business Wire|About: AGN, XCUR

- Exicure (XCUR) to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

- Exicure to Host Conference Call Today at 8:30am ET/7:30am CT

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc., (NASDAQ:XCUR)


 https://www.businesswire.com/news/home/20191114005106/en/ 


 https://seekingalpha.com/news/3519164-exicure-teams-allergan-hair-loss-disorders-shares-24-percent-premarket 


 Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry. 

 https://www.allergan.com/research-and-development/pipeline 


BiotechVortex™

New Global R&D Centre, AI Innovation Centre and a joint investment fund with CICC

image215

 

AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development

PUBLISHED6 November 2019

New Global R&D Centre, AI Innovation Centre and a joint investment fund with CICC to underpin next phase of growth and support transformation of healthcare in China


 https://seekingalpha.com/news/3515077-astrazeneca-launches-1b-china-investment-fund 

Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.

image216

 

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Wed November 6, 2019 7:30 AM|GlobeNewswire|About: BIIB

  • Biogen to gain exclusive commercialization rights to two new ophthalmology biosimilars referencing Lucentis and Eylea in the U.S., Canada, Europe, Japan and Australia

  • Will provide Biogen with commercialization rights for its current anti-TNF biosimilars portfolio in China, adding to its strategic presence in this priority market
     
  • Includes an option to extend the term of its existing European commercial agreement

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.


 https://www.samsungbioepis.com/en/index.do 


 https://investors.biogen.com/news-releases/news-release-details/biogen-expand-biosimilars-portfolio-and-gain-access-additional 

Antengene Corporation today announced it has a licensing agreement with AstraZeneca (LSE/STO/ AZN

image217

 

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Wed November 6, 2019 11:31 AM|PR Newswire|About: AZN, CELG 

 SHANGHAI and LONDON, Nov. 6, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (AZNCF) (LSE/STO/NYSE: AZN)  


 https://www.prnewswire.com/news-releases/antengene-corporation-announces-exclusive-worldwide-license-to-develop-and-commercialize-azd0364-300953003.html 

Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab

image219

 

Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

Fri November 8, 2019 4:05 PM|GlobeNewswire|About: ADROQ3: 11-07-19 Earnings SummaryEPS of $-0.26 misses by $-0.02 Revenue of $4.8M (56.68% Y/Y) beats by $0.76M

BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,


  (see www.clinicaltrials.gov, identifier NCT03396445). 


 https://investors.aduro.com/news-releases/news-release-details/aduro-biotech-announces-presentation-results-first-human-phase-1?field_nir_news_date_value[min]=2019 


Galectin Therapeutics Reaches Agreement w Siemens Healthineers - Collaborate on NASH &Liver Fibrosis

image220

 

Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

Mon November 11, 2019 9:47 AM|GlobeNewswire|About: GALT

NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis.


 https://clinicaltrials.gov/ct2/show/NCT02462967?lead=galectin&phase=12&draw=2&rank=1 


 https://galectintherapeutics.com/ 





BiotechVortex™

AMGN, BGNE

image221

 

BeiGene Announces Global Strategic Oncology Collaboration with Amgen

Thu October 31, 2019 4:00 PM|GlobeNewswire|About: AMGN, BGNE 


 

• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China 

• Companies to Jointly Develop 20 Amgen (AMGN) Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the Global Development Plan

• Amgen to Purchase Approximately $2.7 Billion of BeiGene Shares  

• BeiGene to Hold Analyst and Investor Call on Thursday, October 31 at 8:00 p.m. ET

CAMBRIDGE, Mass. and BEIJING, China, Oct. 31, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE) and Amgen 


 https://www.beigene.com/science-and-product-portfolio/pipeline 


 https://www.amgen.com/media/news-releases/2019/10/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/ 


 https://seekingalpha.com/news/3512709-amgen-teams-beigene-cancer 


 

Amgen (AMGN) Announces Collaboration with BeiGene - Slideshow

Nov. 11, 2019 1:30 PM ET | About: Amgen Inc. (AMGN) 

 https://seekingalpha.com/article/4305471-amgen-amgn-announces-collaboration-beigene-slideshow 

Gilead Sciences, Inc. (GILD) Galapagos NV (GLPGF)

image222

 

Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

Fri November 1, 2019 4:01 PM|GlobeNewswire|About: GLPG

Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD), delivered an exercise notice to Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG) 


 https://seekingalpha.com/news/3513251-gilead-stake-galapagos-25_1-percent 



SYK

image223

 

Stryker announces definitive agreement to acquire Wright Medical

Mon November 4, 2019 7:00 AM|GlobeNewswire|About: SYK 

 Kalamazoo, Michigan, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Stryker (SYK


 https://www.stryker.com/ 

cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies

image224

 

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

Tue November 5, 2019 7:00 AM|Business Wire|About: TAK

− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021

− Potential to be the First CAR Cell Therapy Approved for Outpatient Administration

HOUSTON & OSAKA, Japan--(BUSINESS WIRE)-- The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK) (“Takeda”) 


 https://www.businesswire.com/news/home/20191105005250/en/ 


 https://www.takeda.com/ 


 https://www.mdanderson.org/cancermoonshots/cancer-types/Leukemia_CLL.html 


 https://www.mdanderson.org/cancermoonshots/cancer-types/b-cell-lymphoma.html 


 https://www.mdanderson.org/cancermoonshots/research_platforms/adoptive-cell-therapy.html 


 https://www.mdanderson.org/ 

BiotechVortex™

WALGREENS, SUSAN G. KOMEN AND LLS COLLABORATE TO SUPPORT RESEARCH

image227

 

Walgreens, Susan G. Komen and The Leukemia & Lymphoma Society Collaborate to Support Research in Tough-to-Treat Cancers and Increase Access to Care

Tue October 22, 2019 9:00 AM|Business Wire|About: WBA

$25M, multi-year commitment builds on Walgreens (WBA) efforts to improve the health and well-being of people living with cancer nationwide

DEERFIELD, Ill. & DALLAS & RYE BROOK, N.Y.--(BUSINESS WIRE)-- Walgreens announced today a new collaboration with Susan G. Komen and The Leukemia & Lymphoma Society 


 https://www.businesswire.com/news/home/20191022005311/en/ 


 https://www.lls.org/lls-us-hq/news/walgreens-susan-g-komen-and-lls-collaborate-to-support-research-in-tough-to-treat-cancers-and-increase-access-to-care?news=News%20Releases&newsid=12355 


 https://ww5.komen.org/ 

Abbott's Alinity s Solution

image228

 

The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening

Mon October 21, 2019 9:00 AM|PR Newswire|About: ABT    PR Newswire

ABBOTT PARK, Ill., Oct. 21, 2019 /PRNewswire/ -- Abbott (ABT)


 https://www.prnewswire.com/news-releases/the-australian-red-cross-blood-service-selects-abbotts-alinity-s-solution-for-blood-and-plasma-screening-300941474.html 



CNP-101/TAK-101, immune modifying nanoparticle to induce tolerance to gluten in patients with celiac

image229

 

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Tue October 22, 2019 1:00 AM|Business Wire|About: TAK

− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease

− Takeda (TKPHF) acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease

OSAKA, Japan & CHICAGO--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”)


 https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes 


 https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/ 

QuantiFERON®-TB Gold Plus (QFT®-Plus)

image230

 

QIAGEN’s QuantiFERON®-TB Gold Plus Test Added to the Global Drug Facility Catalog for Public Health Efforts

Tue October 29, 2019 5:05 PM|Business Wire|About: QGEN

  • QIAGEN expands market for gold standard latent TB test to help developing countries fight TB
  • WHO-endorsed test to support communities with the highest need
  • First demonstration of QuantiFERON®-TB Access at the Union World meeting in India

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)


 https://www.businesswire.com/news/home/20191029005850/en/ 


 https://www.who.int/tb/publications/global_report/en/ 


 http://www.stoptb.org/gdf/ 

ABBV will advance= potentiator into clinical development for use in treatments cystic fibrosis (CF)

image231

 

AbbVie Announces Collaboration with Cystic Fibrosis Foundation

Thu October 24, 2019 8:00 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (ABBV)


 https://www.prnewswire.com/news-releases/abbvie-announces-collaboration-with-cystic-fibrosis-foundation-300944388.html 

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT

image232

 

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT

Wed October 30, 2019 6:59 AM|Business Wire|About: BMY

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE:BMY) and LabCentral


 https://www.businesswire.com/news/home/20191030005268/en/ 


 https://www.carminetherapeutics.com/ 

BiotechVortex™

ILMN, QGEN

image233

 

Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Mon October 7, 2019 4:05 PM|Business Wire|About: ILMN, QGEN

Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making

SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- Illumina, Inc. (ILMN) and QIAGEN N.V. (QGEN)


image234

 

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

October 1, 2019 | Microsoft News Center


 

  • Multiyear alliance underpins the Novartis commitment to leverage data & artificial intelligence (AI) to transform how medicines are discovered, developed and commercialized
  • Novartis to establish AI innovation lab to empower its associates to use AI across the business
  • Joint research activities will include co-working environments on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) – starting with tackling personalized therapies for macular degeneration; cell & gene therapy; and drug design

Basel, and Redmond, October 1, 2019

Valiant® TAAA Stent Graft System

image235

 

Medtronic Receives FDA Breakthrough Device Designation for Developing Stent Graft System to Treat Thoracoabdominal Aortic Aneurysm

Tue October 8, 2019 10:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

BLUE NVO

image236

 

bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

Wed October 9, 2019 8:00 AM|Business Wire|About: BLUE

CAMBRIDGE, Mass. and BAGSVÆRD, Denmark--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO)

Abbott (ABT) and Tandem Diabetes Care (TNDM)

image237

 

Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

Tue October 15, 2019 8:00 AM|PR Newswire|About: ABT, TNDMPR Newswire

ABBOTT PARK, Ill. and SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Abbott (ABT) and Tandem Diabetes Care (TNDM)

Living With Diabetes

image238

Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population

Mon October 14, 2019 8:00 AM|PR Newswire|About: CHGCY, IHRT, RHHBY

-- Event Will Broadcast Nationwide On Veteran's Day From The Country Music Hall of Fame, Honoring The One In Four Veterans Living With Diabetes In The U.S.

PR Newswire

INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche (ROCM) (SIX: RO, ROG; OTCQX: RHHBY)


 https://www.prnewswire.com/news-releases/roche-partners-with-iheartmedia-to-present-iheartcountry-one-night-for-our-military-concert-to-bring-further-awareness-of-the-impact-diabetes-has-on-the-nations-veteran-population-300937249.html 


 https://www.research.va.gov/pubs/docs/va_factsheets/Diabetes.pdf 

BiotechVortex™

Pfizer (PFE)

image239

 

Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina

Wed August 21, 2019 10:00 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer (PFE

T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs

image240

 

Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies

Aug 28, 2019 | News, USA

  • Celgene Secures Exclusive Options to Three Immatics TCR-T Targets
  • Immatics to Receive $75 Million Upfront Payment and May Be Eligible for Future Opt-in Exercise, Milestone and Royalty 
  • Immatics Retains Options to Co-Develop or Co-Fund Certain Licensed Products

 Houston, Texas and Tuebingen, Germany, August 28, 2019 – Immatics Biotechnologies GmbH 

CIVO™ multiplexed intratumoral microdosing platform,

image241

 

Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology

Tue August 27, 2019 8:00 AM|PR Newswire|About: BMY

SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences

smart insulin pens into Continuous Glucose Monitoring (CGM) devices

image242

 

Medtronic and Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

Mon September 16, 2019 3:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN and BAGSVÆRD, Denmark, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) (NYSE:MDT), and Novo Nordisk A/S


AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR

image243

 

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

Mon September 9, 2019 7:30 AM|Business Wire|About: ALXN, BBIO, EIDX

- Eidos grants Alexion (ALXN) exclusive license to develop and commercialize AG10 in Japan -

- Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 -

- Agreement expands Alexion’s amyloidosis portfolio -

- Eidos to receive upfront payment of $25 million and equity investment of $25 million, with potential for additional Japanese-based milestone- & royalty-dependent payments -

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc. (BBIO)’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (EIDX) (NASDAQ:EIDX) 

FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens,

image244

 

ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED

- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin

- Two world leaders in diabetes work together to drive meaningful change in care


 ABBOTT PARK, Ill. and PARIS, Sept. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Sanofi  

image245

IDA Ireland

Operations in Ireland

 Pfizer has IDA-supported facilities at five sites in Ireland that employ 3,500 people. It is the largest pharmaceutical sector investor and employer. From an initial investment of €10 million in 1969, Pfizer's total investment in Ireland now stands at nearly €8 billion.  

 https://www.idaireland.com/how-we-help/case-studies/pfizer 


 GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions. 

 https://www.idaireland.com/how-we-help/case-studies/gsk 


 In 1997, Takeda, the largest pharmaceutical company in Japan, established a Formulation Plant in Bray, Wicklow, for the manufacture of three of the company’s blockbuster drugs (Prevacid, Blopress and Actos). The establishment of this facility was paramount to Takeda’s strategy in responding to expanding growth in the European and US markets. This plant has significantly expanded its operation since inception and operates on a 24 hour/7 day basis. 

 https://www.idaireland.com/how-we-help/case-studies/takeda 

Company Overview

 Merck & Co., New Jersey is a global research-driven pharmaceutical company and is the fifth largest pharmaceutical company in the world. Outside North America it is known as MSD. 

BiotechVortex™

Innovation-Lounge with focus on diabetes

image246

 Lilly Germany kicks off Innovation-Lounge with focus on diabetes

by LillyPad 30/07/2019 

 By Dr. Stefanie Beck, Government Affairs Manager Lilly Germany. 

iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps

image247

 

  • LILLY, EVIDATION HEALTH AND APPLE STUDY SHOWS PERSONAL DIGITAL DEVICES MAY HELP IN THE IDENTIFICATION OF MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER'S DISEASE DEMENTIA

Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia

08/08/2019Download PDF

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL)


 https://seekingalpha.com/pr/17597726-lilly-evidation-health-apple-study-shows-personal-digital-devices-may-help-identification 

Optune® Tumor Treating Fields

image248

 

China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China

Mon August 12, 2019 7:30 AM|Business Wire|About: NVCR, ZLAB

SHANGHAI & ST. HELIER, Jersey--(BUSINESS WIRE)-- Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR),


 http://www.zailaboratory.com/products/index.aspx 

Financial Time - Novartis (NVS) to file 50 applications for drug approvals in China by 2023

image249

Novartis bets big on China, 50 new drug applications expected by 2023

Aug. 12, 2019 9:36 AM ET|About: Novartis AG (NVS)|By: , SA News Editor  

Insulet Corporation (PODD)

image250

 

Insulet Omnipod DASH™ System Mobile Apps Now Available for iOS Devices

Fri August 9, 2019 10:05 AM|Business Wire|About: PODD 

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

image251

 

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Fri August 9, 2019 8:30 AM|Business Wire|About: GILD

-- Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks --

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD

 

Québec Provides Access to Biktarvy® for the Treatment of HIV

Thu August 15, 2019 8:00 AM|Canada Newswire|About: GILD 

 MISSISSAUGA, ON, Aug. 15, 2019 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) 

 https://seekingalpha.com/pr/17604746-quebec-provides-access-biktarvy-treatment-hiv 

image252

I-Mab Biopharma Co.

Chinese Drug Developer I-Mab Is Said to File for U.S. IPO By Bloomberg / Aug 03, 2019 02:15 AM / Bus

 

In-licensing: through in-licensing partnerships with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring, we have quickly built our China Portfolio by acquiring multiple innovative clinical stage assets with favorable clinical safety and early efficacy data. In that respect, we are often considered an ideal China partner by our global partners because of our strong development capabilities and proven track record.

Out-licensing: the out-licensing deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In addition, we seek co-development opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have out-licensed three de-prioritized assets and initiated four co-development programs with partners such as ABL Bio, Everest Medicines and WuXi Biologics. The revenue we generated from out-licensing and co-development deals is expected to continue to grow as our pipeline progresses.


 

R&D Site in Shanghai

 Our headquarters is based in Zhangjiang, Pudong, Shanghai. The Shanghai site has a state-of-the-art laboratory facility that hosts both our discovery unit and the CMC research unit (cell line and analytical development). There are also large open-office spaces hosting the R&D organization, the CMC department and the operation teams. Site address: Suites 802, 505, 702, West Tower, 88 Shangke Road, Pudong New District, Shanghai, China. 

 http://www.i-mabbiopharma.com/en/Facilities.html 


 Copyright I-MAB Biopharma Co., Ltd. all rights reserved 2019 

I-Mab Biopharma Co.

 

China Portfolio

image253

Swiss Biotech Association

Global Innovation Index 2019: Switzerland is the world’s most-innovative country

 

  • Wednesday, July 24, 2019 @ 12:00 am

Switzerland is the world’s most-innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the 2019 edition of the Global Innovation Index (GII), which also identifies regional leaders India, South Africa, Chile, Israel and Singapore, with China, Vietnam and Rwanda topping their income groups.


 Switzerland is the world’s most innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the GII 2019.   https://www.wipo.int/global_innovation_index/en/2019/index.html  

Swiss Biotech Association

 

Contact

Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
T: +41 44 455 56 78
E-mail

image254

Varian (VSEA) (NYSE: VAR)

HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

 Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR 

 

NEWS PROVIDED BY Varian   Jul 25, 2019, 03:00 ET


 PALO ALTO, Calif. and STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced that the Karolinska University Hospital Solna in Sweden is the first hospital in Scandinavia to deliver High Dose Rate (HDR) brachytherapy treatments using the new Bravos™ afterloader system 


  http://www.varian.com  


 https://seekingalpha.com/article/4277633-varian-medical-systems-inc-2019-q2-results-earnings-call-slides 


 https://www.varian.com/oncology/products/treatment-delivery/brachytherapy-afterloaders-applicators/bravos 


 https://www.prnewswire.com/news-releases/karolinska-university-hospital-solna-delivers-hdr-brachytherapy-cancer-treatments-with-varian-bravos-afterloader-system-300889555.html 


Karolinska University Hospital

 Karolinska University Hospital is one of Europe’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in development and medical break-throughs.  

 https://www.karolinska.se/?splitoption=splitdecision 

image255

Seoul Innovation QuickFire Challenge: Smart Healthcare

The Challenge - Johnson & Johnson Innovation - JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI), Janssen Korea Ltd.


 

The Challenge 

In 2018, the Asia-Pacific health tech industry had a record-breaking year in total funding, closing at $6.3 billion, making the Asia-Pacific health tech ecosystem the second largest in the world in value, behind only the United States[1]. As the health tech boom surges in the Asia-Pacific, healthcare solutions geared towards medical diagnosis, health management, patient solutions, and population health management garnered multimillion-dollar deals.

Health tech may hold the promise of providing new inroads for the biggest healthcare challenges of our time. From patient care, to data management, personalized medicine and population health, Smart Healthcare tools including blockchain, AI, 3D printing, and wearables, may be the key that unlocks new advances that make a meaningful difference for people around the globe.

That’s why Johnson & Johnson Innovation - JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI), Janssen Korea Ltd. are launching the Seoul Innovation QuickFire Challenge in Smart Healthcare. Up to two innovators with the best idea, technology, or solution that aims to address a health need for the world's population will receive up to KRW150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub, and mentorship from experts at the Johnson & Johnson Family of Companies.

Seoul Innovation QuickFire Challenge in Smart Healthcare.

 Awards

Up to KRW 150,000,000 (~ US $134,000)

  • One-year residency at the Seoul Bio Hub
  • A year of mentorship and coaching from experts in science and commercialization at the Johnson & Johnson Family of Companies
  • Access to the Johnson & Johnson Innovation – JLABS ecosystem

image256

JLABS @ Shanghai

SHANGHAI, June 27, 2019

 

The world’s largest JLABS and the first in Asia Pacific aims to support more than 50 life science start-ups from around the world with the hope to accelerate healthcare innovation in China and globally

SHANGHAI, June 27, 2019 — Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd.

seeking biotech alpha partnerships

Bristol-Myers Squibb & Tsinghua University

image257

 Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer 

Abbvie & Rice University

image258

 AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology 

Johnson & Johnson & Boston University

image259

Johnson & Johnson and Boston University Announce a New Alliance Focused on Tackling Lung Cancer 

Amgen And Cedars-Sinai

image260

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

Thu July 19, 2018 4:00 PM|PR Newswire|About: AMGN 

jlabs-shanghai

image261

Shanghai Lung Cancer Innovation QuickFire Challenge

Biotech & University Partnerships

image262

 "partnerships help foster a culture of entrepreneurship and innovation in the university community.”. 

seeking biotech alpha updates

image263

 Bill Nygren Comments on Bristol-Myers Squibb = "The company’s two most valuable drugs Opdivo and Yervoy should continue to grow revenue as they maintain effectiveness with new tumor types. Bristol Myers Squibb also has the most new molecular agents and the highest number of combinations of agents in trials. Moreover, the company’s R&D and marketing prowess also make it a desired partner for promising academic and small biotech innovators. 

image264

 Bill Nygren - Oakmark Fund manager -  invested in 6.5 million shares of Bristol-Myers Squibb for an average price of $54.03 per share. The manager dedicated 1.85% of his equity portfolio to the position. 

​Ray Dalio - Bridgewater Associates also invested in Bristol-Myers during the quarter.

image265

 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

image266

 Jeff Auxier comments on Merck = Merck beat estimates in the second quarter of 2018 with $10.5 billion in revenues and EPS of $1.06. They were buoyed in the quarter by their signature cancer drug KEYTRUDA which allows the body’s immune system to destroy cancerous cells by blocking a protective enzyme in cancer cells. Sales grew 89% in the quarter to $1.667 billion and are expected to continue to grow to upwards of $13 billion annually by 2026. Recently KEYTRUDA was approved in China and the EU for metastatic melanoma. 

image267

Jeff Auxier Comments on Biogen = Biogen saw revenues increase by 9% to $3.4 billion. Revenue growth was driven by Spinal Muscular Atrophy drug Spinraza which saw a 108% increase in revenue. Spinraza is Biogen’s fastest growing drug which they hope will be able to offset the slowing Multiple Sclerosis product line. Biogen presented the detailed results for the phase II trials of their Alzheimer’s drug BAN2401 on July 25th. The results of the trial were positive with tested patients showing 30% less cognitive decline over 18 months than those who received the placebo, but the presentation garnered a mixed reception and caused Biogen’s stock to fall 9% in after-hours trading. Earlier in July, Biogen announced that the trials of the drug were looking very positive without giving any details, and this announcement may have caused many to anticipate that the results would be better than what was ultimately shown. Currently, Biogen’s stock is hurting from the results announcement, but their outlook is still positive in the long-run due to the strength of their pipeline. Another Alzheimer’s drug in Biogen’s pipeline, Aducanumab, just finished its enrollment for two phase III trials. This drug has been regarded as more promising than BAN2401, and if it is successful Biogen will have the only drug in a $12 billion market.
 

image268

  PR Newswire

THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -Amgen (AMGN) announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S.and global markets.